B-cell neoplasm
Therapeutic area
Hematology
Rare disease
No
- Definition
- A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- B-cell neoplasm
- Therapeutic area
- Hematology
- B-cell neoplasm
- B-cell neoplasm
- lymphoma, B-cell
- Severity
- Unknown
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0004095
- Parent condition
- MONDO:0004805
Related records
Broader conditions (15)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (128)
- A53 diffuse large B-cell lymphoma
- Aggressive B-cell non-Hodgkin lymphoma
- ALK-positive large B-cell lymphoma
- Alpha-heavy chain disease
- B acute lymphoblastic leukemia with DUX4 rearrangement
- B acute lymphoblastic leukemia with PAX5 P80R mutation
- B-cell acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
- B-cell adult acute lymphocytic leukemia
- B-cell childhood acute lymphoblastic leukemia
- B-cell chronic lymphocytic leukemia
- B-cell non-Hodgkin lymphoma
- B-cell prolymphocytic leukemia
- B-lymphoblastic leukemia with MEF2D rearrangement
- B-lymphoblastic leukemia with MYC rearrangement
- B-lymphoblastic leukemia with NUTM1 rearrangement
- B-lymphoblastic leukemia with PAX5alt
- B-lymphoblastic leukemia with TCF3-HLF fusion
- B-lymphoblastic leukemia with ZNF384 rearrangement
- B-lymphoblastic leukemia/lymphoma MLL rearranged
Trials (774)
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 18F-FSPG PET/CT for Cancer Patients on Therapy
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
- A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
- A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
- A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
- A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
- A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
- A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
- A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Approved drugs (2)
Drugs in development (1)
- Bortezomib Phase 2